PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34804015-3	2021	Tivantinib, a non-adenosine triphosphate-competitive c-Met inhibitor, showed an attractive therapeutic effect on advanced HCC patients with high MET-expression in phase 2 study but failed to meet its primary endpoint of prolonging the overall survival (OS) in two phase 3 HCC clinical trials.	ARQ 197	0-10	SAFB like transcription modulator	Homo sapiens	145-148	
34804015-11	2021	Several factors may contribute to the inconsistency between the phase 2 and phase 3 studies of tivantinib, including the sample size, drug dosing, study design, and the rate of MET-High.	ARQ 197	95-105	SAFB like transcription modulator	Homo sapiens	177-180	
34164713-10	2021	Tivantinib reduced levels of both phospho-MET (7/11 patients) and tubulin (4/11 patients) in skin.	ARQ 197	0-10	SAFB like transcription modulator	Homo sapiens	42-45	
33497758-2	2021	Agents targeting MET and its ligand hepatocyte growth factor (HGF) including small molecules such as crizotinib, tivantinib and cabozantinib or antibodies including rilotumumab and onartuzumab have proven their values in different tumors.	ARQ 197	113-123	SAFB like transcription modulator	Homo sapiens	17-20	
32716114-0	2020	A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma.	ARQ 197	65-75	SAFB like transcription modulator	Homo sapiens	102-105	
32980960-8	2021	RESULTS: The antitumor effect of crizotinib and tivantinib correlated with MET gene expression but not with L1-MET transcript or MET protein expressions.	ARQ 197	48-58	SAFB like transcription modulator	Homo sapiens	75-78	
32980960-11	2021	CONCLUSION: MET RNA expression could be useful biomarker for tivantinib and crizotinib targeted therapy in HCC.	ARQ 197	61-71	SAFB like transcription modulator	Homo sapiens	12-15	
32980960-7	2021	Cell proliferation assay was used to assess the effect of crizotinib and tivantinib on the six liver cancer cell lines in correlation with the expression of MET, L1-MET and MET.	ARQ 197	73-83	SAFB like transcription modulator	Homo sapiens	157-160	
32980960-7	2021	Cell proliferation assay was used to assess the effect of crizotinib and tivantinib on the six liver cancer cell lines in correlation with the expression of MET, L1-MET and MET.	ARQ 197	73-83	SAFB like transcription modulator	Homo sapiens	165-168	
32716114-1	2020	A previous randomized phase 2 study of hepatocellular carcinoma revealed that the c-Met inhibitor tivantinib as second-line treatment significantly prolonged progression-free survival in a subpopulation whose tumor samples highly expressed c-Met (MET-high).	ARQ 197	98-108	SAFB like transcription modulator	Homo sapiens	247-250	
32716114-2	2020	Accordingly, this phase 3 study was conducted to evaluate the efficacy of tivantinib as a second-line treatment for Japanese patients with MET-high hepatocellular carcinoma.	ARQ 197	74-84	SAFB like transcription modulator	Homo sapiens	139-142